See more : PT Era Mandiri Cemerlang Tbk (IKAN.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Sanofi (SNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sanofi, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Bambuser AB (publ) (BUSER.ST) Income Statement Analysis – Financial Results
- Airthings ASA (ARTGF) Income Statement Analysis – Financial Results
- Furuno Electric Co., Ltd. (6814.T) Income Statement Analysis – Financial Results
- Jiangsu Shentong Valve Co., Ltd. (002438.SZ) Income Statement Analysis – Financial Results
- GIANTSTEP Inc. (289220.KQ) Income Statement Analysis – Financial Results
Sanofi (SNY)
About Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.03B | 45.39B | 39.18B | 37.37B | 37.63B | 35.68B | 36.22B | 34.70B | 34.86B | 32.00B | 31.29B | 35.96B | 35.06B | 32.04B | 30.75B | 28.82B | 29.25B | 29.49B | 28.49B | 15.03B | 8.03B | 7.46B | 6.49B | 5.96B | 5.35B |
| Cost of Revenue | 14.24B | 13.69B | 12.26B | 12.16B | 11.98B | 11.32B | 11.45B | 10.70B | 10.92B | 10.23B | 10.29B | 11.08B | 10.90B | 8.72B | 7.88B | 7.34B | 7.58B | 7.59B | 7.56B | 3.75B | 1.43B | 1.38B | 1.25B | 1.44B | 1.49B |
| Gross Profit | 31.80B | 31.70B | 26.92B | 25.21B | 25.66B | 24.36B | 24.77B | 24.00B | 23.94B | 21.77B | 21.00B | 24.88B | 24.16B | 23.32B | 22.87B | 21.48B | 21.67B | 21.90B | 20.93B | 11.28B | 6.61B | 6.08B | 5.24B | 4.52B | 3.86B |
| Gross Profit Ratio | 69.07% | 69.83% | 68.72% | 67.47% | 68.18% | 68.27% | 68.40% | 69.16% | 68.68% | 68.03% | 67.10% | 69.20% | 68.90% | 72.79% | 74.37% | 74.55% | 74.08% | 74.27% | 73.47% | 75.05% | 82.26% | 81.50% | 80.69% | 75.82% | 72.11% |
| Research & Development | 6.73B | 6.71B | 5.69B | 5.53B | 6.02B | 6.35B | 5.57B | 5.23B | 5.08B | 4.67B | 4.61B | 4.91B | 4.81B | 4.40B | 4.58B | 4.58B | 4.54B | 4.43B | 4.04B | 7.45B | 1.31B | 1.22B | 1.03B | 945.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00M | 106.00M | 106.00M | 114.00M | -542.00M | -495.00M | 182.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 9.39B | 9.88B | 9.86B | 10.06B | 9.49B | 9.38B | 9.11B | 8.60B | 8.95B | 8.54B | 7.57B | 7.33B | 7.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.77B | 10.54B | 9.56B | 9.39B | 9.88B | 9.93B | 10.16B | 9.59B | 9.50B | 8.57B | 8.11B | 9.13B | 8.54B | 7.57B | 7.33B | 7.17B | 7.87B | 8.02B | 8.24B | 4.50B | 2.47B | 2.43B | 2.31B | 2.02B | 1.89B |
| Other Expenses | 6.45B | 2.57B | 2.53B | 2.40B | 2.53B | 1.70B | 1.66B | 1.65B | 2.23B | 3.02B | 3.13B | 3.02B | 3.62B | 3.58B | 3.14B | -23.00M | 3.20B | 3.45B | 2.93B | -360.73M | -246.94M | -189.64M | -208.00M | -17.00M | 995.00M |
| Operating Expenses | 23.94B | 19.81B | 17.77B | 17.32B | 18.43B | 17.99B | 17.39B | 16.48B | 16.81B | 16.25B | 15.84B | 17.05B | 16.97B | 15.55B | 15.05B | 11.72B | 15.61B | 15.90B | 15.21B | 11.59B | 3.54B | 3.46B | 3.13B | 2.94B | 2.89B |
| Cost & Expenses | 38.16B | -7.29B | 30.03B | 29.48B | 30.41B | -7.73B | -7.42B | -7.18B | -7.44B | -5.64B | -5.86B | -7.29B | 27.87B | 24.27B | 22.93B | 19.06B | 23.20B | 23.49B | 22.77B | 15.34B | 4.96B | 4.84B | 4.38B | 4.39B | 4.38B |
| Interest Income | 546.00M | 206.00M | 40.00M | 53.00M | 141.00M | 164.00M | 147.00M | 68.00M | 178.00M | 193.00M | 109.00M | 93.00M | 140.00M | 105.00M | 24.00M | 65.00M | 190.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.09B | 461.00M | 368.00M | 390.00M | 444.00M | 495.00M | 420.00M | 924.00M | 559.00M | 598.00M | 609.00M | 751.00M | 552.00M | 467.00M | 324.00M | 335.00M | 329.00M | 1.54B | 4.71B | 2.53B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.78B | 3.70B | 3.13B | 3.27B | 3.75B | 3.46B | 3.15B | 2.99B | -2.48B | -2.75B | -3.39B | -3.20B | 4.91B | 5.44B | 5.00B | 245.00M | 4.48B | 6.73B | 5.95B | 2.52B | 117.52M | 179.16M | 301.00M | 241.00M | 236.00M |
| EBITDA | 12.00B | 14.06B | 11.29B | 17.51B | 7.11B | 9.36B | 10.28B | 10.36B | 10.23B | 9.87B | 9.62B | 11.43B | 10.64B | 11.40B | 11.40B | 10.48B | 10.40B | 12.12B | 11.67B | 2.25B | 3.19B | 3.00B | 2.41B | 1.82B | 1.21B |
| EBITDA Ratio | 26.06% | 30.98% | 27.47% | 26.13% | 26.15% | 26.24% | 28.38% | 29.86% | 29.36% | 30.84% | 30.74% | 34.77% | 30.35% | 35.59% | 36.98% | 34.73% | 35.56% | 42.26% | 47.01% | 14.99% | 39.67% | 37.49% | 37.10% | 30.49% | 22.56% |
| Operating Income | 7.88B | 16.79B | 8.13B | 8.08B | 7.69B | 12.43B | 12.01B | 12.34B | 12.71B | 12.62B | 13.01B | 15.70B | 5.73B | 5.96B | 6.37B | 9.76B | 5.92B | 5.73B | 7.45B | -262.61M | 3.07B | 2.62B | 2.11B | 1.58B | 971.00M |
| Operating Income Ratio | 17.11% | 37.00% | 20.74% | 21.63% | 20.45% | 34.84% | 33.15% | 35.57% | 36.46% | 39.45% | 41.58% | 43.67% | 16.35% | 18.61% | 20.70% | 33.88% | 20.24% | 19.43% | 26.13% | -1.75% | 38.21% | 35.09% | 32.46% | 26.45% | 18.15% |
| Total Other Income/Expenses | -722.00M | -166.00M | -328.00M | 24.00M | -229.00M | 228.00M | -188.00M | -720.00M | -403.00M | -458.00M | -459.00M | -1.81B | -542.00M | -362.00M | -300.00M | -232.00M | -139.00M | -981.21M | -2.11B | -588.67M | 58.76M | -108.64M | 34.00M | -17.00M | -48.00M |
| Income Before Tax | 7.15B | 10.49B | 7.80B | 13.80B | 2.82B | 4.90B | 5.62B | 5.81B | 5.22B | 5.61B | 4.52B | 6.17B | 5.32B | 5.60B | 6.07B | 9.49B | 5.78B | 4.75B | 2.64B | -1.84B | 3.13B | 2.51B | 2.14B | 1.56B | 0.00 |
| Income Before Tax Ratio | 15.54% | 23.11% | 19.91% | 36.94% | 7.50% | 13.75% | 15.50% | 16.75% | 14.98% | 17.52% | 14.45% | 17.15% | 15.17% | 17.48% | 19.73% | 32.94% | 19.76% | 16.10% | 9.27% | -12.25% | 38.94% | 33.63% | 32.98% | 26.16% | 0.00% |
| Income Tax Expense | 1.60B | 2.01B | 1.56B | 1.81B | 139.00M | 481.00M | 1.72B | 1.33B | 709.00M | 1.21B | 726.00M | 1.11B | 455.00M | 1.24B | 1.36B | 2.76B | 687.93M | 800.12M | 477.04M | 818.09M | 1.06B | 747.13M | 842.00M | 611.00M | 346.00M |
| Net Income | 5.40B | 8.37B | 6.22B | 12.29B | 2.81B | 4.31B | 3.89B | 4.71B | 4.29B | 4.39B | 3.72B | 4.97B | 5.69B | 4.36B | 5.27B | 7.19B | 5.27B | 4.01B | 2.26B | -2.66B | 2.07B | 1.76B | 1.59B | 985.00M | 625.00M |
| Net Income Ratio | 11.73% | 18.44% | 15.89% | 32.90% | 7.46% | 12.07% | 10.75% | 13.57% | 12.30% | 13.72% | 11.88% | 13.81% | 16.24% | 13.60% | 17.12% | 24.94% | 18.02% | 13.58% | 7.92% | -17.70% | 25.80% | 23.61% | 24.43% | 16.52% | 11.68% |
| EPS | 4.31 | 6.69 | 4.97 | 9.81 | 2.33 | 3.45 | 3.08 | 3.42 | 3.38 | 3.25 | 2.75 | 3.70 | 4.27 | 3.34 | 4.03 | 2.94 | 3.91 | 2.97 | 1.68 | -2.92 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| EPS Diluted | 4.30 | 6.66 | 4.95 | 9.76 | 2.31 | 3.43 | 3.07 | 3.39 | 3.34 | 3.21 | 2.71 | 3.68 | 4.26 | 3.33 | 4.03 | 2.94 | 3.89 | 2.95 | 1.67 | -2.91 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| Weighted Avg Shares Out | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.27B | 1.29B | 1.32B | 1.32B | 1.32B | 1.33B | 1.32B | 1.31B | 1.31B | 1.31B | 1.35B | 1.35B | 1.34B | 910.30M | 702.75M | 727.69M | 731.71M | 731.23M | 730.78M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.32B | 1.33B | 1.34B | 1.33B | 1.33B | 1.31B | 1.31B | 1.31B | 1.35B | 1.36B | 1.35B | 914.80M | 705.12M | 729.27M | 731.71M | 731.23M | 730.78M |
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Press Release: Availability of the Q3 2024 Aide mémoire
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Source: https://incomestatements.info
Category: Stock Reports